Please login to the form below

Not currently logged in
Email:
Password:

darapladib

This page shows the latest darapladib news and features for those working in and with pharma, biotech and healthcare.

GSK takes anti-inflammatory drug into phase III as heart therapy

GSK takes anti-inflammatory drug into phase III as heart therapy

GSK's cardiovascular pipeline suffered a setback last month when coronary artery disease therapy darapladib failed a second phase III trial.

Latest news

  • Second darapladib failure disappoints GSK Second darapladib failure disappoints GSK

    Second darapladib failure disappoints GSK. Drug unable to demonstrate effectiveness in acute coronary syndrome. ... Prospects for GlaxoSmithKline's coronary artery disease therapy darapladib have all but disappeared after it failed to show efficacy in a

  • Moving parts Moving parts

    Meanwhile, costly phase III failures arrived in the shape of Lilly's depression drug edivoxetine and GlaxoSmithKline's highly anticipated new coronary heart disease drug candidate darapladib, which both flunked

  • GSK hit as darapladib flunks phase III test GSK hit as darapladib flunks phase III test

    GSK hit as darapladib flunks phase III test. Heart disease drug disappoints in late-stage trial. ... GlaxoSmithKline's highly anticipated new coronary heart disease (CHD) drug candidate darapladib has disappointed in a phase III trial.

  • GSK's Chinese sales hit by scandal, say analysts GSK's Chinese sales hit by scandal, say analysts

    darapladib for atherosclerosis which could have "vast potential" if it reaches the market.

  • GSK submits albiglutide for European approval GSK submits albiglutide for European approval

    Albiglutide is, along with lupus treatment Benlysta and heart disease drug darapladib, one of a trio of drugs GSK has developed with Human Genome Sciences.

More from news
Approximately 2 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Pharma deals during July 2012 Pharma deals during July 2012

    These are Benlysta (belimumab), an antibody approved for the treatment of lupus; darapladib, a phase III small molecule drug for the treatment of cardiovascular disease; and albiglutide, an albumin-fusion protein ... There is $150m in potential licence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics